HOME >> MEDICINE >> NEWS
Treatment-Resistant Depression: Results of Latest Electromagnetic Stimulation Study Show Promise

eters below the brain's surface. Unlike ECT for depression, rTMS does not require anesthesia or analgesics."

Study subjects were antidepressant-free for one week prior to rTMS and received 10 daily treatments (10 trains of five seconds each, 25 seconds apart) at a frequency of 10 Hz. Seventy-eight percent of patients experienced mild-moderate discomfort at the site of stimulation, two patients who experienced severe pain in the treatment site dropped out of the study and eight percent of patients experienced a posttreatment headache.

The mean age of patients treated was 52 years. " rTMS seems most promising for older adults and for treatment-resistant patients with depression," says Dr. McDonald, who directs the Fuqua Center for Late-Life Depression at Wesley Woods.

Also collarborating on the study were Charles M. Epstein, M.D., associate professor of neurology at Emory; Liquong He, M.D., formerly with Emory; Autumn L. Clark, B.S., study coordinator in Emory's department of psychiatry and behavioral sciences; Fred A. Marstellar, Ph.D., associate professor of psychiatry and behavioral sciences at Emory; and John Woodard, Ph.D., of the Georgia State University Memory Assessment Clinic.

The study was supported by a private grant from the Fuqua Foundation.


'"/>

Contact: Sarah Goodwin
sgoodwi@emory@emory.edu
404-727-3366
Emory University Health Sciences Center
17-May-1999


Page: 1 2

Related medicine news :

1. Heart transplant survival: Results may be key to rejection prevention, detection, treatment
2. Docetaxel versus paclitaxel in breast cancer Results of worlds first head to head trial
3. Results from first clinical trial using GVG to treat addiction
4. Results of first chronic treatment study with oral EXANTA(TM) (ximelagatran)
5. Media Advisory-- Results of California autism epidemiology study to be unveiled
6. Results of Yale study confirm aspirin helpful in preventing a first heart attack
7. Results of NUVANCE (IL-4 receptor) in Phase I/II study in asthma patients featured at AAAAI Late-Breaker Abstract and Asthma Therapy Sessions
8. Yale study shows way to re-stimulate brain cell growth: Results could boost understanding of Alzheimers, other brain disorders
9. Results of NUVANCE phase I/II asthma trial presented
10. ILEX Oncology & LeukoSite report results from pivotal Phase II CAMPATH (R) trial; Results suggest new hope for refractory chronic lymphocytic leukemia
11. UI Study Yields Encouraging Results For New Breast Cancer Treatment

Post Your Comments:
(Date:7/31/2015)... Chicago, IL (PRWEB) , ... July 31, 2015 , ... ... which is currently going on in Chicago at Grant Park. The festival ... every corner of North America to Chicago for the annual Lollapalooza. This unique ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... run by GoodThreads. The store can be accessed by visiting http://www.curemeso.org/store . ... which are customizable. The best part: whenever a product is purchased, the Meso ...
(Date:7/31/2015)... ... July 31, 2015 , ... There’s no better way to enjoy ... comes time to cook the next meal, making July the most appropriate to be ... grilling tips and recipes. , Make the next cookout different than the ones in ...
(Date:7/31/2015)... ... , ... Coco Libre announced today that their flagship Organic Coconut Water will ... US Open of Surfing, July 25 through August 2 in Huntington Beach, California. Coco ... market, is a natural choice given the Open’s commitment to sustainable practices. , ...
(Date:7/31/2015)... ... 31, 2015 , ... According to the article published July 27 on My News ... contained and extinguished by the city’s fire department before it caused major damage throughout the ... of the fire, and it was a fire alarm system that tipped off fire fighters ...
Breaking Medicine News(10 mins):Health News:Cheap 2015 Lollapalooza Tickets: Ticket Down Slashes Ticket Prices on Lollapalooza Tickets at Grant Park in Chicago for Saturday, August 1st and Sunday, August 2nd 2Health News:Mesothelioma Organization Launches New Store 2Health News:Mesothelioma Organization Launches New Store 3Health News:King Kullen Honors National Hot Dog and Blueberry Month 2Health News:King Kullen Honors National Hot Dog and Blueberry Month 3Health News:Coco Libre Brings Eco-conscious Hydration to Vans US Open of Surfing 2Health News:Article on Recent Pasadena Courtroom Fire Highlights the Effectiveness of Fire Alarm Systems, Says Fire Protection Group Inc 2Health News:Article on Recent Pasadena Courtroom Fire Highlights the Effectiveness of Fire Alarm Systems, Says Fire Protection Group Inc 3
(Date:7/31/2015)... SAN DIEGO , July 31, 2015  Eisai ... Ltd. (Headquarters: Tokyo , President and ... Inc. (Headquarters: San Diego, California , ... HALO") have signed a clinical collaboration agreement to evaluate ... in combination with Halozyme,s investigational drug PEGPH20 (PEGylated recombinant ...
(Date:7/31/2015)... According to a new market ... Analyzers (BIA), Dual-Energy X-ray Absorptiometry (DEXA), Skinfold Calipers, Air ... & Forecast to 2019", published by MarketsandMarkets, the global ... 2014 and is estimated to grow to $1,425.7 Million ... 2014 to 2019. Browse 41 market ...
(Date:7/30/2015)... , July 30, 2015 Edwards Lifesciences Corporation (NYSE: ... heart valves and hemodynamic monitoring, today announced that Robert ... Directors. "Bob is an ardent champion for innovation ... privilege to have him on Edwards, board as we pursue ... Edwards, chairman and CEO.  "Bob has provided a valuable perspective ...
Breaking Medicine Technology:Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 2Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 5Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 6Body Composition Analyzers Market Worth $1,425.7 Million by 2019 2Body Composition Analyzers Market Worth $1,425.7 Million by 2019 3Body Composition Analyzers Market Worth $1,425.7 Million by 2019 4
Cached News: